explore -WSS

explore

author：focus 2025-10-01 00:06:14 - browse：6

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Zyn nicotine pouches become unlikely player in latest culture war

leisure time

WSS

Goldman Sachs launches $650M fund for life science investments

Feng Zhang CRISPR delivery startup lays off quarter of staff

Syphilis numbers in the United States reach record heights

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Humana’s losses in Medicare Advantage tank its stock

The biotech scorecard for Q1: 17 stock

hotspot

explore

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

U.K. sequencing study surfaces new findings about tumor DNA

In age of alternative facts, a scholarly course on calling out crap

Wegovy leads to weight loss. Can it treat depression, too?

Medical records are filled with copy

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

United colonoscopy coverage change 'may cost lives,' doctors say

Pancreatic cancer early detection could be helped by AI

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How generative AI ratchets up security threats for health systems

leisure time

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Feng Zhang CRISPR delivery startup lays off quarter of staff

Videos point to link between seizures and unexplained toddler deaths

White House pharmacy plagued with problems, investigation finds

Biogen walks away from Aduhelm, years after polarizing approval

3 medical device trends to watch in 2024

Wikipedia

leisure time

focus

focus